-
1.发明申请公开(公告)号：US20180002435A1
公开(公告)日：2018-01-04
申请号：US15546630
申请日：2016-01-25
发明人： Barbara Johnson SASU , Arvind RAJPAL , Philippe DUCHATEAU , Alexandre JUILLERAT , Julien VALTON
IPC分类号： C07K16/28 , C07K14/705 , G01N15/10 , G01N15/14 , C12N5/0783 , C07K14/725 , G01N15/00
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.
-
2.发明公开公开(公告)号：US20240228636A1
公开(公告)日：2024-07-11
申请号：US18481797
申请日：2023-10-05
发明人： Barbara Johnson SASU , Arvind RAJPAL , Philippe DUCHATEAU , Alexandre JUILLERAT , Julien VALTON
IPC分类号： C07K16/28 , A61K35/17 , A61K39/00 , A61K39/395 , C07K14/705 , C07K14/725 , C07K14/735 , C07K16/30 , C12N5/00 , C12N5/0783 , G01N15/01 , G01N15/10 , G01N15/1031 , G01N15/14 , G01N15/149
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/001176 , A61K39/39558 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C12N5/0093 , C12N5/0636 , C12N5/0638 , G01N15/1031 , G01N15/14 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N2510/00 , G01N2015/016 , G01N2015/1006 , G01N2015/1028 , G01N15/149
摘要： A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.
-
3.发明申请公开(公告)号：US20190328783A1
公开(公告)日：2019-10-31
申请号：US16092414
申请日：2017-04-13
申请人： CELLECTIS
IPC分类号： A61K35/17 , C07K14/725 , C12N5/0783 , C12N15/85
摘要： The present invention relates to therapeutic cells for immunotherapy to treat patients with cancer. In particular, the inventors develop a method of engineering prodrug-specific hypersensitive T-cell, which can be depleted in vivo by the administration of said specific prodrug in case of occurrence of a serious adverse event. The invention opens the way to safer and tunable adoptive immunotherapy strategies for treating cancer.
-
公开(公告)号：US20180000914A1
公开(公告)日：2018-01-04
申请号：US15546604
申请日：2016-01-25
申请人： Cellectis
发明人： Julien VALTON , Philippe DUCHATEAU , Alexandre JUILLERAT , Arvind RAJPAL , Barbra Johnson SASU , Julianne SMITH
IPC分类号： A61K39/00 , C07K14/725 , C12N5/0783 , C07K14/735 , A61K39/395 , C07K16/28 , C07K14/705
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from an anti-HSP70 monoclonal antibody, conferring specific immunity against HSP70 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating in particular leukemia.
-
公开(公告)号：US20180002427A1
公开(公告)日：2018-01-04
申请号：US15546619
申请日：2016-01-25
申请人： CELLECTIS
发明人： Julianne SMITH , Julien VALTON , Philippe DUCHATEAU , Alexandre JUILLERAT , Arvind RAJPAL , Barbra Johnson SASU
IPC分类号： C07K16/28 , C12N5/00 , C07K16/30 , A61K39/00 , A61K35/17 , C12N5/0783 , C07K14/725
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： The present invention relates to a new generation of chimeric antigen receptors (CAR) referred to as multi-chain CARs, which are made specific to the antigen CLL1. Such CARs aim to redirect immune cell specificity and reactivity toward malignant cells expressing the tumor antigen CLL1. The alpha, beta and gamma polypeptides composing these CARs are designed to assemble in juxtamembrane position, which forms flexible architecture closer to natural receptors, that confers optimal signal transduction. The invention encompasses the polynucleotides, vectors encoding said multi-chain CAR and the isolated cells expressing them at their surface, in particularly for their use in immunotherapy. The invention opens the way to efficient adoptive immunotherapy strategies for treating cancer, especially leukemia.
-
公开(公告)号：US20240360196A1
公开(公告)日：2024-10-31
申请号：US18607387
申请日：2024-03-15
发明人： Arvind RAJPAL , Shobha Chowdary POTLURI , Laurent POIROT , Alexandre JUILLERAT , Thomas Charles PERTEL , Donna Marie STONE , Barbra Johnson SASU
IPC分类号： C07K14/705 , A61K35/17 , A61K39/00 , C07K14/725 , C07K16/28 , C07K16/30 , C12N5/0783
CPC分类号： C07K14/70503 , A61K35/17 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/2803 , C07K16/3069 , C12N5/0636 , A61K2039/5156 , C07K2317/622 , C07K2317/76 , C07K2319/03 , C07K2319/70 , C07K2319/74 , C12N2510/00
摘要： The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising
an extracellular domain comprising an antigen binding domain,
a transmembrane domain and,
an intracellular domain
wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein
X1 is an amino acid
X2 is an amino acid
X3 is an amino acid and
X4 is V or I.-
公开(公告)号：US20180051089A1
公开(公告)日：2018-02-22
申请号：US15546623
申请日：2016-01-25
申请人： Cellectis
发明人： Roman GALETTO , Barbara Johnson SASU , Arvind RAJPAL , Philippe DUCHATEAU , Alexandre JUILLERAT , Julien VALTON , Mathieu SIMON
IPC分类号： C07K16/28 , A61K35/17 , A61K39/00 , C07K14/725 , C07K16/30 , C12N5/00 , C12N5/0783
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： The present invention relates to a TCR KO—or TCR KO and dCK KO—engineered immune cells expressing a Chimeric Antigen Receptors (CAR) specific for CD123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward CD123-expressing cells, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CD123 CARs are particularly suited for treating relapse refractory AML and blastic plasmacytoid dendritic cell neoplasm and for use as a treatment before bone marrow transplantation.
-
公开(公告)号：US20180044399A1
公开(公告)日：2018-02-15
申请号：US15525906
申请日：2015-11-09
发明人： Arvind RAJPAL , Shobha Chowdary POTLURI , Laurent POIROT , Alexandre JUILLERAT , Thomas Charles PERTEL , Donna Marie STONE , Barbra Johnson SASU
IPC分类号： C07K14/705 , C07K14/725 , A61K35/17 , C07K16/28 , C12N5/0783
CPC分类号： C07K14/70503 , A61K35/17 , A61K2039/5156 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/2803 , C07K16/3069 , C07K2317/622 , C07K2317/76 , C07K2319/03 , C07K2319/70 , C07K2319/74 , C12N5/0636 , C12N2510/00
摘要： The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or
-
9.发明申请公开(公告)号：US20180009895A1
公开(公告)日：2018-01-11
申请号：US15546633
申请日：2016-01-25
申请人： Cellectis
发明人： Julianne SMITH , Julien VALTON , Philippe DUCHATEAU , Alexandre JUILLERAT , Arvind RAJPAL , Barbra Johnson SASU
IPC分类号： C07K16/28 , A61K39/00 , C07K16/30 , C07K14/725 , C12N5/0783 , C12N5/00
CPC分类号： C07K16/2866 , A61K35/17 , A61K39/0011 , A61K39/39558 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , A61K2039/6056 , A61K2039/64 , C07K14/7051 , C07K14/70517 , C07K14/70535 , C07K14/70578 , C07K16/2803 , C07K16/2887 , C07K16/3061 , C07K2317/24 , C07K2317/53 , C07K2317/56 , C07K2317/622 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C12N5/0093 , C12N5/0636 , C12N5/0638 , C12N2510/00 , G01N15/1031 , G01N15/14 , G01N2015/008 , G01N2015/1006 , G01N2015/1081 , G01N2015/149
摘要： The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
